Physician profile
Thaddeus S Nowinski
NPI 1578561957
$1,015.74
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $312 · 2020: $65.62 · 2021: $180 · 2022: $206 · 2023: $166 · 2024: $86.32.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $253.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $252.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $154.35 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $130.62 | 2019-2023 | Cequa |
| Abbvie INC. | $127.32 | 2022-2024 | |
| Horizon Therapeutics Plc | $113.16 | 2019-2022 | |
| Alcon Vision LLC | $97.89 | 2021-2023 | Simbrinza |
| Oyster Point Pharma, INC. | $54.89 | 2022-2023 | Tyrvaya |
| Novartis Pharmaceuticals Corporation | $51.92 | 2019-2023 | |
| Dompe US, INC. | $48.31 | 2022-2024 | Oxervate |
| Shire North American Group INC | $46.76 | 2019 | |
| Carl Zeiss Meditec, INC. | $35.73 | 2019-2020 | |
| Allergan, INC. | $29.70 | 2019 | |
| Carl Zeiss Meditec USA, INC. | $27.62 | 2024 | Cirrus Hd-Oct |
| Bausch & Lomb Americas INC. | $24.60 | 2023 | Vyzulta |
| Glaukos Corporation | $17.49 | 2023 | |
| Rayner Intraocular Lenses Limited | $17.30 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ocular Therapeutix, INC. | $14.71 | 2019 | |
| Aerie Pharmaceuticals, INC. | $13.71 | 2021 | |
| Biotissue Holdings INC. | $9.66 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thaddeus Nowinski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.